KM-3907(KM-3907) - 药物靶点：CLDN1 x CLDN3_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

dual claudin-3/claudin-4 mAb(Kyowa Hakko Kirin)

靶点

CLDN1 x CLDN3

作用机制

CLDN1抑制剂(Claudin 1抑制剂)、CLDN3抑制剂(claudin 3 inhibitors)

治疗领域

肿瘤

在研适应症-

非在研适应症

肿瘤

原研机构

Kyowa Kirin Co., Ltd.

在研机构-

非在研机构

Kyowa Kirin Co., Ltd.

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 KM-3907 相关的临床结果

登录后查看更多信息

100 项与 KM-3907 相关的转化医学

登录后查看更多信息

100 项与 KM-3907 相关的专利（医药）

登录后查看更多信息

1

项与 KM-3907 相关的文献（医药）

2010-11-01·Anticancer research

Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4.

Article

作者: Furuya, Akiko ; Suzuki, Masayo ; Ando, Hiroshi ; Kawamoto, Shinobu ; Kato-Nakano, Mariko ; Nakamura, Kazuyasu ; Ohta, So

BACKGROUNDBecause human claudin-3 and claudin-4 (CLDN3 and CLDN4) are overexpressed in a variety of carcinomas, they are promising targets for cancer therapy. The aim of the present study was to generate a dual-targeting monoclonal antibody against CLDN3 and CLDN4 and evaluate its antitumour activity.MATERIALS AND METHODSBALB/c mice were immunised with CLDN4-expressing Chinese hamster ovary cells and cell-based screening was performed. The antibody-binding epitope of CLDN3 and CLDN4 and the antitumour activity of the antibody were evaluated.RESULTSA monoclonal antibody, KM3907 (IgG2a), which recognised CLDN3 and CLDN4, but not CLDN5, CLDN6 and CLDN9, was successfully isolated. The binding assay of KM3907 revealed that KM3907 recognised the extracellular loop 1 of CLDN3 and CLDN4. Mouse human chimeric IgG1 induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and treatment with murine KM3907 significantly inhibited tumour formation in SCID mice in vivo.CONCLUSIONA dual-targeting monoclonal antibody against CLDN3 and CLDN4 is a promising strategy for cancer immunotherapy.

100 项与 KM-3907 相关的药物交易

登录后查看更多信息